Concepedia

Author

Gerald McMahon

Maxygen (United States)

Also Known As

G MCMAHON, G McMahon, G. MCMAHON, G. McMahon, G. Mcmahon, Gerald J . Mcmahon, Gerald J. McMahon, Gerald McMahon, Gerald Mcmahon

113

Publications

16.1K

Citations

47

H-Index

101

Concepts

All Affiliations

Maxygen (United States)Massachusetts Institute of TechnologyThe University of Texas MD Anderson Cancer Center
GM

About

Gerald McMahon is an author at Maxygen (United States) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

36

42

12.3K

2

Natural Sciences

10

10

2.8K

3

Health Sciences

6

6

739

4

Engineering

5

5

230

5

Social Sciences

1

1

19

Gerald McMahon

×

65

Publications

15.6K

Citations

46

H-Index

YearCitations

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Gabriele Bergers, Rolf A. Brekken, Gerald McMahon,

Nature Cell Biology

2000

2.8K

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin,

PubMed

2003

2K

Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors

Moosa Mohammadi, Gerald McMahon, Li Sun,

Science

1997

1.1K

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

T. Annie T. Fong, Laura K. Shawver, Li Sun,

PubMed

1999

1K

Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids

Ker Yu, William Bayona, Caleb B. Kallen,

Journal of Biological Chemistry

1995

703

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Alexander Laird, Peter Vajkoczy, Laura K. Shawver,

PubMed

2000

497

Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones:  A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases

Li Sun, Ngoc Quang Tran, Flora Tang,

Journal of Medicinal Chemistry

1998

486

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

Yongsheng Ma, Shan Zeng, Dean D. Metcalfe,

Blood

2002

447

Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis

Amir Abdollahi, Minglun Li, Ping Gong,

The Journal of Experimental Medicine

2005

380

Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.

Ling Geng, Edwin F. Donnelly, Gerald McMahon,

PubMed

2001

338

Page 1